newsfilter
← Latest News
GlobeNewswire·

Trevena Reports Second Quarter 2022 Results and Provides Business Update

OLINVYK post-approval strategy advances with positive topline cognitive function data and continued enrollment in VOLITION clinical outcomes study Phase 1 study for TRV045, a novel S1P receptor modulator, on track for year-end data readout; single asc